H-HeFTHot Line 6Heart Failure
Hydralazine-Isosorbide Dinitrate for Patients with Heart Failure and Reduced Ejection Fraction
Hydralazine-isosorbide dinitrate in patients with heart failure and reduced ejection fraction
Presenting authorLars KøberHeart Failure / Cardiomyopathy · Rigshospitalet, Copenhagen University Hospital, DenmarkLars Køber is a Clinical Professor in the Department of Clinical Medicine at the University of Copenhagen and a Professor of Cardiology and Consultant at Rigshospitalet, Copenhagen University Hospital. He graduated from the University of Copenhagen and is a specialist in internal medicine and cardiology. His research focuses on heart failure, acute coronary syndromes, cardiovascular epidemiology, and large-scale randomized clinical trials.
Overview
Await ESC 2026 data before changing HFrEF therapy; leaves open hydralazine-isosorbide dinitrate efficacy.
Discussion
Expert reaction lands here the moment H-HeFT reports.
Key Points
- Investigating hydralazine-isosorbide dinitrate aims to determine clinical efficacy in individuals managing chronic heart failure with reduced ejection fraction.
- Late-breaking clinical trial presented at the ESC Congress evaluates therapeutic outcomes of combination vasodilator therapy, with formal trial results pending.
- Supports ongoing clinical assessment of fixed-dose hydralazine and isosorbide dinitrate regimens to optimize treatment paradigms for heart failure patients.